Skip to content
Screener

Regenxbio RGNX Asset turnover

Asset turnover at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.4×0.0×
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
0.6×
Biogen logo
BiogenBIIB
0.3×0.0×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
0.4×-0.1×
EyePoint, Inc. logo
EyePoint, Inc.EYPT
-0.2×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.6×+0.1×

Other financials

Income statement

See full
Revenue$108.0M+406%
Gross profit$14.9M+35.7%
Operating income$29.3M+146%
Net income$22.7M+132%
EPS (diluted)$0.43+131%

Balance sheet

See full
Cash & equivalents$36.5M-54.1%
Total debt$69.0M-11.3%
Total equity$71.8M-66.4%
Total assets$386.6M-33.5%

Cash flow

See full
Operating cash flow-$62.2M-26.1%
CapEx$760.0K+94.4%
Free cash flow-$63.0M-26.7%

Valuation

See full
Market cap$707.66M+87.8%
Enterprise value$740.13M+97.4%
P/S4.1×+1.6×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-94.1%-9.3pp
Net margin-112.6%-0.1pp
FCF margin-143.1%-456pp

Returns & leverage

See full
Return on equity-137.6%-817pp
Debt / equity+0.6×
Current ratio2.9×-0.3×

Where this comes from

Calculated from Regenxbio’s reported figures.

Based on trailing twelve months.

The source filing: Regenxbio’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 7:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336725

FAQ

What is Regenxbio's asset turnover?
Regenxbio (RGNX) reported asset turnover of 0.4× in Q2 2026.
How has Regenxbio's asset turnover changed year-over-year?
Regenxbio's asset turnover increased by 33.2% year-over-year, from 0.3× to 0.4×.
What is the long-term trend for Regenxbio's asset turnover?
Over 5 years (2020 to 2025), Regenxbio's asset turnover has grown at a 7.7% compound annual growth rate (CAGR), from 0.3× to 0.4×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.

Ask your AI about Regenxbio's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude